A New Approach to Treating Brain Cancer: HDT Bio Launches Canadian Clinical Program at McGill University

Gillette Archived • July 12, 2026 • 2 views

HDT Bio Canada Inc. partners with McGill University and The Neuro to advance HDT-401, an investigational locally administered RNA immune activator, into Phase 1 clinical evaluation for glioblastoma in Canada

Source: https://www.gillettenewsrecord.com/search/?f=rss&t=article&l=50&s=start_time&sd=desc - Read Original

FB X ✉️

Discussion (0)

Please log in to post a comment.

No comments yet. Be the first to share your thoughts!